1-chloro-7-(3-pyridyl)-3,6-dioxaheptane | 118715-73-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-chloro-7-(3-pyridyl)-3,6-dioxaheptane
• 英文别名: 5-Chloro-3-oxo-1-(3-picolinoxy)pentane；3-<<2-(2-chloroethoxy)ethoxy>methyl>pyridine；3-{[2-(2-chloroethoxy)ethoxy]methyl}pyridine；3-[2-(2-Chloroethoxy)ethoxymethyl]pyridine
• CAS: 118715-73-4
• 化学式: C₁₀H₁₄ClNO₂
• 分子量: 215.68
• InChiKey: KFEGZGPYALDBEF-UHFFFAOYSA-N

物化性质

• 沸点：
  316.9±27.0 °C(Predicted)
• 密度：
  1.140±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-chloro-7-(3-pyridyl)-3,6-dioxaheptane 在 氢氧化钾 、 sodium hydride 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 24.5h， 生成 2,2-Bis(6-carboxy-2-pyridyl)-3,5-dioxo-8-(3-picolinoxy)octane
  参考文献：
  名称：

  Synthesis and Coordination Properties of Pendant Arm Dipyridylmethane Derivatives

  摘要：

  Dipyridylmetane dicarboxylic acids with pendant arms containing pyridine groups were prepared. Cu(II) was shown to form square pyramidal complexes with the ligands. Depending on the structure of the pendant arm, the apical position was occupied either by a water molecule or by a pyridyl group from the same molecule or form a neighboring molecule. The reason for the different behavior of the ligands is suggested to be due to stereoelectronically induced conformational preferences of the ligands.

  DOI：

  10.1021/jo00087a012
• 作为产物：
  描述：

  3-吡啶甲醇 、 1-tosyl-5-chloro-3-oxapentane 在 氢氧化钾 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以55%的产率得到1-chloro-7-(3-pyridyl)-3,6-dioxaheptane
  参考文献：
  名称：

  Rhodium(III) cage compounds based on diphenylglycoluril

  摘要：

  DOI：

  10.1021/ja00188a022

文献信息

• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。
• Thiazolidinone compounds and use thereof
  申请人：National Health Research Institutes

  公开号：US10544113B2

  公开（公告）日：2020-01-28

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有用于治疗阿片受体相关疾病的式 (I) 化合物的药物组合物。还公开了一种使用此类化合物治疗阿片受体相关疾病的方法。进一步公开了两组式(I)的噻唑烷酮化合物：(i)对映体过量大于 90%的化合物和(ii)各自被氘取代的化合物。
• Made, A. W. van der; Nolte, R. J. M.; Drenth, W., Recueil des Travaux Chimiques des Pays-Bas, 1990, vol. 109, # 11, p. 537 - 551
  作者：Made, A. W. van der、Nolte, R. J. M.、Drenth, W.

  DOI：——

  日期：——
• [EN] THIAZOLIDINONE COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS DE THIAZOLIDINONE ET LEUR UTILISATION
  申请人：SHIH CHUAN

  公开号：WO2017155910A1

  公开（公告）日：2017-09-14

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.